POU domain class 2-associating factor 1 peptide presented by Human Leukocyte Antigen B*07:02 (BOB1/HLA-B*07:02)

BOB1 (POU domain class 2-associating factor 1, POU2AF1) is a B-cell-specific transcriptional coactivator that plays a critical role in the formation of germinal centers and the differentiation of B-cells into plasma cells (UniProt Q16633). In the context of immunotherapy, a specific peptide fragment of the BOB1 protein is processed and presented on the cell surface by the Human Leukocyte Antigen (HLA) allele B*07:02. This peptide-MHC complex serves as a highly specific target for T-cell receptor (TCR)-engineered T-cell therapies, particularly in B-cell malignancies such as multiple myeloma and mantle cell lymphoma where BOB1 is overexpressed (Jahn et al., 2015, Nature Medicine). Because BOB1 expression is restricted to the B-cell lineage, therapeutic targeting of the BOB1/HLA-B*07:02 complex allows for the selective destruction of malignant B-cells. However, this approach may also lead to the depletion of healthy B-cells, a condition known as B-cell aplasia. Experimental TCR-T cell therapies have demonstrated the ability to recognize this complex and induce potent cytolytic activity against tumor cells in vitro and in vivo (Jahn et al., 2015). This target represents a personalized medicine approach, requiring patients to be positive for both the BOB1 antigen and the HLA-B*07:02 MHC allele.

Other names

POU2AF1 peptide/HLA-B*07:02OBF-1 peptide/HLA-B*07:02OCA-B peptide/HLA-B*07:02BOB.1 peptide/HLA-B*07:02B-cell-specific coactivator OBF-1 peptide/HLA-B*07:02

T-cell receptor (TCR) mediated recognition of the peptide-MHC complex leading to T-cell activation and directed cytotoxicity against the target cell.